BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,026 | -77.7% | 9,216 | -93.6% | 0.01% | -80.6% |
| Q4 2022 | $1,090,171 | -28.8% | 143,067 | -7.2% | 0.03% | -42.6% |
| Q3 2022 | $1,532,000 | +168.3% | 154,090 | +145.1% | 0.05% | +107.7% |
| Q2 2022 | $571,000 | -58.3% | 62,880 | +115.3% | 0.03% | -76.1% |
| Q3 2021 | $1,369,000 | +242.2% | 29,204 | +344.8% | 0.11% | +220.6% |
| Q2 2021 | $400,000 | +33.3% | 6,566 | +34.8% | 0.03% | +21.4% |
| Q1 2021 | $300,000 | -38.0% | 4,870 | -62.3% | 0.03% | -9.7% |
| Q3 2020 | $484,000 | -31.6% | 12,906 | -40.6% | 0.03% | -36.7% |
| Q2 2020 | $708,000 | – | 21,718 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |